Abstract
The quantification of Bcr-Abl transcript numbers in chronic myelogenous leukemia (CML) patients described here uses simultaneous competitive PCR amplification of the target gene (Bcr-Abl) and a reference gene (porphobilinogen deaminase; Pbgd) together with a single composite competitor molecule for both targets based on heterologous sequences. Using this technique, Bcr-Abl transcript numbers could be reproducibly determined even in clinical samples known to harbour poor quality RNA.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
DNA Primers / chemistry
-
DNA, Complementary / analysis
-
Electrophoresis, Agar Gel
-
Gene Expression Regulation, Neoplastic / genetics
-
Genes, abl / genetics*
-
Genetic Vectors / genetics
-
Humans
-
Hydroxymethylbilane Synthase / genetics
-
Interferons / therapeutic use
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism*
-
Polymerase Chain Reaction / methods*
-
Transcription, Genetic / genetics*
Substances
-
DNA Primers
-
DNA, Complementary
-
Interferons
-
Hydroxymethylbilane Synthase